Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur Neuropsychopharmacol. 2014 Apr;24(4):575-84. doi: 10.1016/j.euroneuro.2013.12.009. Epub 2013 Dec 21.

Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia.

Author information

  • 1Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Huispostnummer A 00.241, Postbus 85500, 3508 GA Utrecht, Utrecht, The Netherlands. Electronic address: a.maat@umcutrecht.nl.
  • 2Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Huispostnummer A 00.241, Postbus 85500, 3508 GA Utrecht, Utrecht, The Netherlands.
  • 3Pro Persona Mental Health Care, Expertise Center for Psychosis, UMC St Radboud, Huispostnummer 958, Postbus 9101, 6500 HB Nijmegen, Nijmegen, The Netherlands.
  • 4DeltaBouman Psychiatric Teaching Hospital, Poortugaal, Delta Psychiatrisch Centrum, Afdeling Dorpsblik, Postbus 800, 3170 DZ Poortugaal, The Netherlands.
  • 5Department of Neuroscience, University Medical Center Groningen, University of Groningen, Groningen, Faculteit Medische Wetenschappen/UMCG, A Deusinglaan 2, 9718 AW Groningen, The Netherlands.

Abstract

To date, only few studies have examined the impact of medication on social cognition and none have examined the effects of aripiprazole in this respect. The goal of this 8-week, randomized, multicenter, open-label study was to examine the effects of aripiprazole and risperidone on social cognition and neurocognition in individuals with schizophrenia. Eighty schizophrenia patients (DSM-IV-TR) aged 16-50 years were administered multiple computerized measures of social cognition and neurocognition including reaction times at baseline and the end of week 8. Social functioning was mapped with the Social Functioning scale and Quality of Life scale. The study ran from June 2005 to March 2011. Scores on social cognitive and neurocognitive tests improved with both treatments, as did reaction time. There were few differences between the two antipsychotics on (social) cognitive test-scores. The aripiprazole group performed better (more correct items) on symbol substitution (P=.003). Aripiprazole was also superior to risperidone on reaction time for emotional working memory and working memory (P=.006 and P=.023, respectively). Improvements on these tests were correlated with social functioning. In conclusion, aripiprazole and risperidone showed a similar impact on social cognitive test-scores. However, aripiprazole treatment produced a greater effect on patients' processing speed compared to risperidone, with these improvements being associated with concurrent improvements in social functioning. Further research on the long-term effects of aripiprazole on cognition is warranted.

Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

KEYWORDS:

Aripiprazole; Neurocognition; Risperidone; Schizophrenia; Social Cognition

PMID:
24418213
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk